**Efficacy and safety of different agents for the treatment of bacterial vaginosis: a systematic review and network meta-analysis**

**Content list**

**eTable 1 PRISMA2020 checklist**

**eTable 2 PubMed search strategy and result**

**eTable 3 Embase search strategy and result**

**eFigure 1 Risk of bias summary**

**eFigure 2 Risk of bias graph**

**eFigure 3 Direct meta-analysis of clinical cure rates**

**eFigure 4 Direct meta-analysis of the incidence of adverse reactions**

**eFigure 5 Direct meta-analysis of cure rates for oral drug therapy**

**eFigure 6 Direct meta-analysis of cure rates for local vaginal administration**

**eFigure 7 Network meta-analysis of forest maps of clinical cure rates**

**eFigure 8 Network meta-analysis of the incidence of adverse reactions in forest maps**

**eFigure 9 Network meta-analysis of forest maps of cure rates for oral drug therapy**

**eFigure 10 Network meta-analysis of the forest map of cure rate of local vaginal administration**

**eFigure 11 SUCRA efficacy ranking curve of clinical cure success rate,SUCRA = cumulative ranking surface**

**eFigure 12 SUCRA efficacy ranking curve is the incidence of adverse reactions, SUCRA = cumulative ranking surface**

**eFigure 13 SUCRA efficacy ranking curve is the cure rate of oral drug treatment, SUCRA = cumulative ranking surface**

**eFigure 14 SUCRA efficacy ranking curve is the cure rate of vaginal drug treatment, SUCRA = cumulative ranking surface**

**eFigure 15 Funnel plot of a network meta-analysis of clinical cure success rates**

**eFigure 16 Funnel plot of a network meta-analysis of the incidence of adverse reactions**

**eFigure 17 Funnel plot of a network meta-analysis of cure rates for oral drug therapy**

**eFigure 18 Funnel plot of a network meta-analysis of cure rates for vaginal smear therapy**

| Section and Topic | Item # | Checklist item | Location where item is reported |
| --- | --- | --- | --- |
| TITLE | | |  |
| Title | 1 | Identify the report as a systematic review. | 1 |
| ABSTRACT | | |  |
| Abstract | 2 | See the PRISMA 2020 for Abstracts checklist. | 1 |
| INTRODUCTION | | |  |
| Rationale | 3 | Describe the rationale for the review in the context of existing knowledge. | 2 |
| Objectives | 4 | Provide an explicit statement of the objective(s) or question(s) the review addresses. | 2 |
| METHODS | | |  |
| Eligibility criteria | 5 | Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. | 3 |
| Information sources | 6 | Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted. | 3 |
| Search strategy | 7 | Present the full search strategies for all databases, registers and websites, including any filters and limits used. | 3 |
| Selection process | 8 | Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. | 3 |
| Data collection process | 9 | Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. | 3 |
| Data items | 10a | List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect. | 6 |
| 10b | List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. | 4 |
| Study risk of bias assessment | 11 | Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process. | 4 |
| Effect measures | 12 | Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results. | 7 |
| Synthesis methods | 13a | Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)). | 4 |
| 13b | Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions. | 4 |
| 13c | Describe any methods used to tabulate or visually display results of individual studies and syntheses. | 4 |
| 13d | Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. | 4 |
| 13e | Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression). | 4 |
| 13f | Describe any sensitivity analyses conducted to assess robustness of the synthesized results. | Not applicable |
| Reporting bias assessment | 14 | Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases). | 4 |
| Certainty assessment | 15 | Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. | 4 |
| RESULTS | | |  |
| Study selection | 16a | Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram. | 5 |
| 16b | Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded. | 5 |
| Study characteristics | 17 | Cite each included study and present its characteristics. | 5 |
| Risk of bias in studies | 18 | Present assessments of risk of bias for each included study. | 7 |
| Results of individual studies | 19 | For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots. | 7-11 |
| Results of syntheses | 20a | For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies. | 8 |
| 20b | Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect. | 7-11 |
| 20c | Present results of all investigations of possible causes of heterogeneity among study results. | Not applicable |
| 20d | Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. | Not applicable |
| Reporting biases | 21 | Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed. | Not applicable |
| Certainty of evidence | 22 | Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. | 7-11 |
| DISCUSSION | | |  |
| Discussion | 23a | Provide a general interpretation of the results in the context of other evidence. | 12 |
| 23b | Discuss any limitations of the evidence included in the review. | 13 |
| 23c | Discuss any limitations of the review processes used. | 13 |
| 23d | Discuss implications of the results for practice, policy, and future research. | 12-13 |
| OTHER INFORMATION | | |  |
| Registration and protocol | 24a | Provide registration information for the review, including register name and registration number, or state that the review was not registered. | 4 |
| 24b | Indicate where the review protocol can be accessed, or state that a protocol was not prepared. | 4 |
| 24c | Describe and explain any amendments to information provided at registration or in the protocol. | 4 |
| Support | 25 | Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review. | 12 |
| Competing interests | 26 | Declare any competing interests of review authors. | 12 |
| Availability of data, code and other materials | 27 | Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. | 12 |

*From:*  Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>


**eTable 1 PRISMA2020 checklist**

|  |  |  |  |
| --- | --- | --- | --- |
| Search number | Query | Results | Time |
| 1 | "Vaginosis, Bacterial"[Mesh] | 3,567 | 1:32:48 |
| 2 | ((((((((Bacterial Vaginitides[Title/Abstract]) OR (Vaginitides, Bacterial[Title/Abstract])) OR (Bacterial Vaginosis[Title/Abstract])) OR (Vaginitis, Nonspecific[Title/Abstract])) OR (Nonspecific Vaginitis[Title/Abstract])) OR (Bacterial Vaginoses[Title/Abstract])) OR (Vaginoses, Bacterial[Title/Abstract])) OR (Bacterial Vaginitis[Title/Abstract])) OR (Vaginitis, Bacterial[Title/Abstract]) | 8,324 | 1:36:17 |
| 3 | ("Vaginosis, Bacterial"[Mesh]) OR (((((((((Bacterial Vaginitides[Title/Abstract]) OR (Vaginitides, Bacterial[Title/Abstract])) OR (Bacterial Vaginosis[Title/Abstract])) OR (Vaginitis, Nonspecific[Title/Abstract])) OR (Nonspecific Vaginitis[Title/Abstract])) OR (Bacterial Vaginoses[Title/Abstract])) OR (Vaginoses, Bacterial[Title/Abstract])) OR (Bacterial Vaginitis[Title/Abstract])) OR (Vaginitis, Bacterial[Title/Abstract])) | 8,980 | 1:37:04 |
| 4 | "Clindamycin"[Mesh] | 6,187 | 1:38:40 |
| 5 | ((((((((((((Chlolincocin[Title/Abstract]) OR (7-Chloro-7-deoxylincomycin[Title/Abstract])) OR (7 Chloro 7 deoxylincomycin[Title/Abstract])) OR (Chlorlincocin[Title/Abstract])) OR (Dalacin C[Title/Abstract])) OR (Clindamycin Monohydrochloride[Title/Abstract])) OR (Monohydrochloride, Clindamycin[Title/Abstract])) OR (Clindamycin Monohydrochloride, Monohydrate[Title/Abstract])) OR (Monohydrate Clindamycin Monohydrochloride[Title/Abstract])) OR (Monohydrochloride, Monohydrate Clindamycin[Title/Abstract])) OR (Cleocin[Title/Abstract])) OR (Clindamycin Hydrochloride[Title/Abstract])) OR (Hydrochloride, Clindamycin[Title/Abstract]) | 174 | 1:40:30 |
| 6 | ("Clindamycin"[Mesh]) OR (((((((((((((Chlolincocin[Title/Abstract]) OR (7-Chloro-7-deoxylincomycin[Title/Abstract])) OR (7 Chloro 7 deoxylincomycin[Title/Abstract])) OR (Chlorlincocin[Title/Abstract])) OR (Dalacin C[Title/Abstract])) OR (Clindamycin Monohydrochloride[Title/Abstract])) OR (Monohydrochloride, Clindamycin[Title/Abstract])) OR (Clindamycin Monohydrochloride, Monohydrate[Title/Abstract])) OR (Monohydrate Clindamycin Monohydrochloride[Title/Abstract])) OR (Monohydrochloride, Monohydrate Clindamycin[Title/Abstract])) OR (Cleocin[Title/Abstract])) OR (Clindamycin Hydrochloride[Title/Abstract])) OR (Hydrochloride, Clindamycin[Title/Abstract])) | 6,247 | 1:40:43 |
| 7 | "Metronidazole"[Mesh] | 13,834 | 1:42:04 |
| 8 | (((((((((((((((((((2-Methyl-5-nitroimidazole-1-ethanol[Title/Abstract]) OR (2 Methyl 5 nitroimidazole 1 ethanol[Title/Abstract])) OR (Satric[Title/Abstract])) OR (Trichazol[Title/Abstract])) OR (Trichopol[Title/Abstract])) OR (Trivazol[Title/Abstract])) OR (Metronidazole Phosphoester[Title/Abstract])) OR (Vagilen[Title/Abstract])) OR (Bayer 5360[Title/Abstract])) OR (Metronidazole Phosphate[Title/Abstract])) OR (Danizol[Title/Abstract])) OR (Flagyl[Title/Abstract])) OR (Gineflavir[Title/Abstract])) OR (Metric[Title/Abstract])) OR (Metrodzhil[Title/Abstract])) OR (MetroGel[Title/Abstract])) OR (Metrogyl[Title/Abstract])) OR (Metronidazole Hydrochloride[Title/Abstract])) OR (Metronidazole Monohydrochloride[Title/Abstract])) OR (Clont[Title/Abstract]) | 39,601 | 1:44:18 |
| 9 | ("Metronidazole"[Mesh]) OR ((((((((((((((((((((2-Methyl-5-nitroimidazole-1-ethanol[Title/Abstract]) OR (2 Methyl 5 nitroimidazole 1 ethanol[Title/Abstract])) OR (Satric[Title/Abstract])) OR (Trichazol[Title/Abstract])) OR (Trichopol[Title/Abstract])) OR (Trivazol[Title/Abstract])) OR (Metronidazole Phosphoester[Title/Abstract])) OR (Vagilen[Title/Abstract])) OR (Bayer 5360[Title/Abstract])) OR (Metronidazole Phosphate[Title/Abstract])) OR (Danizol[Title/Abstract])) OR (Flagyl[Title/Abstract])) OR (Gineflavir[Title/Abstract])) OR (Metric[Title/Abstract])) OR (Metrodzhil[Title/Abstract])) OR (MetroGel[Title/Abstract])) OR (Metrogyl[Title/Abstract])) OR (Metronidazole Hydrochloride[Title/Abstract])) OR (Metronidazole Monohydrochloride[Title/Abstract])) OR (Clont[Title/Abstract])) | 53,119 | 1:53:29 |
| 10 | "Probiotics"[Mesh] | 24,816 | 1:54:06 |
| 11 | ((randomized controlled trial[Publication Type]) OR (randomized[Title/Abstract])) OR (placebo[Title/Abstract]) | 1,028,967 | 1:54:49 |
| 12 | ((((("Vaginosis, Bacterial"[Mesh]) OR (((((((((Bacterial Vaginitides[Title/Abstract]) OR (Vaginitides, Bacterial[Title/Abstract])) OR (Bacterial Vaginosis[Title/Abstract])) OR (Vaginitis, Nonspecific[Title/Abstract])) OR (Nonspecific Vaginitis[Title/Abstract])) OR (Bacterial Vaginoses[Title/Abstract])) OR (Vaginoses, Bacterial[Title/Abstract])) OR (Bacterial Vaginitis[Title/Abstract])) OR (Vaginitis, Bacterial[Title/Abstract]))) OR (("Clindamycin"[Mesh]) OR (((((((((((((Chlolincocin[Title/Abstract]) OR (7-Chloro-7-deoxylincomycin[Title/Abstract])) OR (7 Chloro 7 deoxylincomycin[Title/Abstract])) OR (Chlorlincocin[Title/Abstract])) OR (Dalacin C[Title/Abstract])) OR (Clindamycin Monohydrochloride[Title/Abstract])) OR (Monohydrochloride, Clindamycin[Title/Abstract])) OR (Clindamycin Monohydrochloride, Monohydrate[Title/Abstract])) OR (Monohydrate Clindamycin Monohydrochloride[Title/Abstract])) OR (Monohydrochloride, Monohydrate Clindamycin[Title/Abstract])) OR (Cleocin[Title/Abstract])) OR (Clindamycin Hydrochloride[Title/Abstract])) OR (Hydrochloride, Clindamycin[Title/Abstract])))) OR (("Metronidazole"[Mesh]) OR ((((((((((((((((((((2-Methyl-5-nitroimidazole-1-ethanol[Title/Abstract]) OR (2 Methyl 5 nitroimidazole 1 ethanol[Title/Abstract])) OR (Satric[Title/Abstract])) OR (Trichazol[Title/Abstract])) OR (Trichopol[Title/Abstract])) OR (Trivazol[Title/Abstract])) OR (Metronidazole Phosphoester[Title/Abstract])) OR (Vagilen[Title/Abstract])) OR (Bayer 5360[Title/Abstract])) OR (Metronidazole Phosphate[Title/Abstract])) OR (Danizol[Title/Abstract])) OR (Flagyl[Title/Abstract])) OR (Gineflavir[Title/Abstract])) OR (Metric[Title/Abstract])) OR (Metrodzhil[Title/Abstract])) OR (MetroGel[Title/Abstract])) OR (Metrogyl[Title/Abstract])) OR (Metronidazole Hydrochloride[Title/Abstract])) OR (Metronidazole Monohydrochloride[Title/Abstract])) OR (Clont[Title/Abstract])))) OR ("Probiotics"[Mesh])) AND (((randomized controlled trial[Publication Type]) OR (randomized[Title/Abstract])) OR (placebo[Title/Abstract])) | 8,716 | 1:55:32 |


**eTable 2 PubMed search strategy and result**

|  |  |  |  |
| --- | --- | --- | --- |
| No. | Query | Results | Date |
| #1 | 'bacterial vaginosis'/exp OR 'bacterial vaginosis' | 6678 | 14-Oct-23 |
| #2 | 'bacterial vaginitides':ab,ti | 0 | 14-Oct-23 |
| #3 | 'vaginitides, bacterial':ab,ti | 0 | 14-Oct-23 |
| #4 | 'bacterial vaginosis':ab,ti | 6289 | 14-Oct-23 |
| #5 | 'vaginitis, nonspecific':ab,ti | 3 | 14-Oct-23 |
| #6 | 'nonspecific vaginitis':ab,ti | 119 | 14-Oct-23 |
| #7 | 'bacterial vaginoses':ab,ti | 6 | 14-Oct-23 |
| #8 | 'vaginoses, bacterial':ab,ti | 0 | 14-Oct-23 |
| #9 | 'bacterial vaginitis':ab,ti | 150 | 14-Oct-23 |
| #10 | 'vaginitis, bacterial':ab,ti | 29 | 14-Oct-23 |
| #11 | #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 | 6889 | 14-Oct-23 |
| #12 | 'clindamycin'/exp OR 'clindamycin' | 64823 | 14-Oct-23 |
| #13 | 'chlolincocin':ab,ti | 1 | 14-Oct-23 |
| #14 | '7-chloro-7-deoxylincomycin':ab,ti | 7 | 14-Oct-23 |
| #15 | '7 chloro 7 deoxylincomycin':ab,ti | 7 | 14-Oct-23 |
| #16 | 'chlorlincocin':ab,ti | 0 | 14-Oct-23 |
| #17 | 'dalacin c':ab,ti | 20 | 14-Oct-23 |
| #18 | 'clindamycin monohydrochloride':ab,ti | 0 | 14-Oct-23 |
| #19 | 'monohydrochloride, clindamycin':ab,ti | 0 | 14-Oct-23 |
| #20 | 'clindamycin monohydrochloride, monohydrate':ab,ti | 0 | 14-Oct-23 |
| #21 | 'monohydrate clindamycin monohydrochloride':ab,ti | 0 | 14-Oct-23 |
| #22 | 'monohydrochloride, monohydrate clindamycin':ab,ti | 0 | 14-Oct-23 |
| #23 | 'cleocin':ab,ti | 41 | 14-Oct-23 |
| #24 | 'clindamycin hydrochloride':ab,ti | 127 | 14-Oct-23 |
| #25 | 'hydrochloride, clindamycin':ab,ti | 12 | 14-Oct-23 |
| #26 | #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 | 64832 | 14-Oct-23 |
| #27 | 'metronidazole'/exp OR 'metronidazole' | 84413 | 14-Oct-23 |
| #28 | '2-methyl-5-nitroimidazole-1-ethanol':ab,ti | 6 | 14-Oct-23 |
| #29 | '2 methyl 5 nitroimidazole 1 ethanol':ab,ti | 6 | 14-Oct-23 |
| #30 | 'satric':ab,ti | 1 | 14-Oct-23 |
| #31 | 'trichazol':ab,ti | 0 | 14-Oct-23 |
| #32 | 'trichopol':ab,ti | 43 | 14-Oct-23 |
| #33 | 'trivazol':ab,ti | 0 | 14-Oct-23 |
| #34 | 'metronidazole phosphoester':ab,ti | 0 | 14-Oct-23 |
| #35 | 'vagilen':ab,ti | 0 | 14-Oct-23 |
| #36 | 'bayer 5360':ab,ti | 2 | 14-Oct-23 |
| #37 | 'metronidazole phosphate':ab,ti | 6 | 14-Oct-23 |
| #38 | 'danizol':ab,ti | 0 | 14-Oct-23 |
| #39 | 'flagyl':ab,ti | 574 | 14-Oct-23 |
| #40 | 'gineflavir':ab,ti | 0 | 14-Oct-23 |
| #41 | 'metric':ab,ti | 50674 | 14-Oct-23 |
| #42 | 'metrodzhil':ab,ti | 0 | 14-Oct-23 |
| #43 | 'metrogel':ab,ti | 23 | 14-Oct-23 |
| #44 | 'metrogyl':ab,ti | 30 | 14-Oct-23 |
| #45 | 'metronidazole hydrochloride':ab,ti | 25 | 14-Oct-23 |
| #46 | 'metronidazole monohydrochloride':ab,ti | 0 | 14-Oct-23 |
| #47 | 'clont':ab,ti | 15 | 14-Oct-23 |
| #48 | #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 | 135115 | 14-Oct-23 |
| #49 | 'probiotic agent'/exp OR 'probiotic agent' | 53732 | 14-Oct-23 |
| #50 | 'random':ab,ti | 436173 | 14-Oct-23 |
| #51 | 'placebo':ab,ti | 366850 | 14-Oct-23 |
| #52 | 'double-blind':ab,ti | 225581 | 14-Oct-23 |
| #53 | #50 OR #51 OR #52 | 862270 | 14-Oct-23 |
| #54 | #11 OR #26 OR #48 OR #49 | 242915 | 14-Oct-23 |
| #55 | #53 AND #54 | 10461 | 14-Oct-23 |

**eTable 3 Embase search strategy and result**




**eFigure 1 Risk of bias summary**




**eFigure 2 Risk of bias graph**




**eFigure 3 Direct meta-analysis of clinical cure rates**




**eFigure 4 Direct meta-analysis of the incidence of adverse reactions**




**eFigure 5 Direct meta-analysis of cure rates for oral drug therapy**




**eFigure 6 Direct meta-analysis of cure rates for local vaginal administration**




**eFigure 7 Network meta-analysis of forest maps of clinical cure rates**




**eFigure 8 Network meta-analysis of the incidence of adverse reactions in forest maps**




**eFigure 9 Network meta-analysis of forest maps of cure rates for oral drug therapy**




**eFigure 10 Network meta-analysis of the forest map of cure rate of local vaginal administration**

****


**eFigure 11 SUCRA efficacy ranking curve of clinical cure success rate,SUCRA = cumulative ranking surface**




**eFigure 12 SUCRA efficacy ranking curve is the incidence of adverse reactions, SUCRA = cumulative ranking surface**




**eFigure 13 SUCRA efficacy ranking curve is the cure rate of oral drug treatment, SUCRA = cumulative ranking surface**




**eFigure 14 SUCRA efficacy ranking curve is the cure rate of vaginal drug treatment, SUCRA = cumulative ranking surface**




**eFigure 15 Funnel plot of a network meta-analysis of clinical cure success rates**



**eFigure 16 Funnel plot of a network meta-analysis of the incidence of adverse reactions**



**eFigure 17 Funnel plot of a network meta-analysis of cure rates for oral drug therapy**



**eFigure 18 Funnel plot of a network meta-analysis of cure rates for vaginal smear therapy**